A baboon model for endometriosis: implications for fertility by Hastings, Julie M & Fazleabas, Asgerally T
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
Reproductive Biology and 
Endocrinology
Open Access Review
A baboon model for endometriosis: implications for fertility
Julie M Hastings and Asgerally T Fazleabas*
Address: Department of Obstetrics and Gynecology (MC808), College of Medicine, University of Illinois at Chicago, 820 S Wood Street, Chicago, 
Illinois, 60612, USA
Email: Julie M Hastings - julieh@uic.edu; Asgerally T Fazleabas* - asgi@uic.edu
* Corresponding author    
Abstract
Endometriosis is one of the most common causes of chronic pelvic pain and infertility in women in
the reproductive age group. Although the existence of this disease has been known for over 100
years our current knowledge of its pathogenesis and the pathophysiology of its related infertility
remains unclear. Several reasons contribute to our lack of knowledge, the most critical being the
difficulty in carrying out objective long-term studies in women. Thus, we and others have developed
a model of this disease in the non-human primate, the baboon (Papio anubis). Intraperitoneal
inoculation of autologous menstrual endometrium results in the development of endometriotic
lesions with gross morphological characteristics similar to those seen in the human. Multiple factors
have been implicated in endometriosis-associated infertility. We have described aberrant levels of
factors involved in multiple pathways important in the establishment of pregnancy, in the
endometrium of baboons induced with endometriosis. Specifically, we have observed dysregulation
of proteins involved in invasion, angiogenesis, methylation, cell growth, immunomodulation, and
steroid hormone action. These data suggest that, in an induced model of endometriosis in the
baboon, an increased angiogenic capacity, decreased apoptotic potential, progesterone resistance,
estrogen hyper-responsiveness, and an inability to respond appropriately to embryonic signals
contribute to the reduced fecundity associated with this disease.
Introduction
Endometriosis, the presence of endometrial glands and
stroma outside of the uterine cavity, is one of the most
common causes of chronic pelvic pain and infertility: it
affects 1 in 10 women in the reproductive-age group [1].
This incidence increases up to 30% in patients with infer-
tility [2]. Several theories have been proposed to explain
the etiology of endometriosis; however, the most widely
accepted hypothesis for the development of endometrio-
sis is Sampson's theory of retrograde menstruation, in
which fragments of menstrual endometrium are refluxed
through the fallopian tubes into the peritoneal cavity [3].
However, although retrograde menstruation occurs in 70–
90% of women in the reproductive age group, endometri-
osis is only diagnosed in 10% of this population [1,4].
While the existence of this disease has been known for
more than one hundred years, our current knowledge of
the pathogenesis of this spontaneous evolution and the
pathophysiology of the related infertility remains unclear.
Several factors contribute to this lack of understanding.
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Most significantly, at the time of clinical presentation,
most women have established disease; furthermore, the
subsequent time taken to diagnosis can be extremely long
[5,6]. Individual differences in progression and symp-
tomatology of the disease create difficulties in conducting
objective long-term studies in women. Finally, endome-
triosis only occurs naturally in humans and non-human
primates. Thus, because ethical and practical considera-
tions limit studies in the human, an appropriate animal
model needs to be developed.
Experimental models of endometriosis have been devel-
oped in immunocompromized rodents that allow the
transplantation of human endometrial tissue with limited
graft rejection [7-9]. Other investigators perform
allotransplantation of uterine endometrium from syn-
geneic mice [10]. These models are advantageous because
they have limited cost and large study groups can be inves-
tigated. Moreover, these animals are usually "inbred" and
experimental results are more reproducible than those
seen in "out-bred" human and non-human primate sub-
jects, with less biological variation. However, while
rodents provide an excellent first-line approach to investi-
gate the etiology of this enigmatic disease, there are sev-
eral limitations of these models, least of which are the lack
of a menstrual cycle and the spontaneous development of
endometriosis.
Spontaneous endometriosis has been reported in the rhe-
sus macaque (Macaca mulatta), the Japanese macaque
(Macaca fuscata), the pig-tailed macaque (Macaca nemes-
trima), and the Kenya baboon (Papio doguera), leading
researchers to evaluate the use of the non-human primate
as a model to investigate endometriosis [11-14]. It was
proposed that iatrogenically induced retrograde menstru-
ation would result in the development of endometriosis,
supporting the hypothesis of Sampson. Indeed, endome-
triosis was experimentally induced in rhesus macaques by
surgical diversion of the cervix into the abdomen; how-
ever, endometriosis was found in only 50% of the animals
[15,16]. Supracervical ligation impeded uterine outflow
in baboons, illustrated by a decreased duration of ante-
grade menstruation and increased retrograde menstrua-
tion. Although this study size was small, histologically-
confirmed endometriosis was observed in the two ani-
mals as early as three months after supracervial ligation
[17]. Increased levels of endometriosis were observed in
rhesus macaques subjected to prolonged exposure to the
dioxin 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCCD);
however, the follow-up time of this study was ten years
[18].
More recent pioneering work from D'Hooghe and co-
workers demonstrated that endometriosis develops natu-
rally in a subset of female olive and yellow baboons (Papio
anubis and Papio cynocephalus, respectively) maintained in
captivity and that the incidence of clinical and biopsy-
proven endometriosis in the baboon is a progressive dis-
ease that increases with the duration of captivity [19,20].
D'Hooghe et al., further demonstrated that experimental
induction of endometriosis by inoculation of endometrial
currettings into the peritoneal cavity produced both read-
ily recognizable pelvic endometriotic lesions that were
macroscopically similar to those seen in women with
spontaneous endometriosis and an increased rate of infer-
tility [21,22].
We now report studies using a modified version of this
baboon model of induced endometriosis, to demonstrate
the aberrant expression of several genes in the eutopic and
ectopic endometria of these animals. We propose that
such changes may mediate the establishment and progres-
sion of endometriosis and the reduced fecundity associ-
ated with this enigmatic disease.
An Experimental Model of Endometriosis in the 
Baboon
Endometriosis was experimentally induced in female
Papio anubis baboons, with documented regular men-
strual cycles, by intraperitoneal inoculation with men-
strual endometrium on two consecutive menstrual cycles.
Menstrual endometrium (0.84 ± 0.22 g) was harvested on
day 1 or 2 of menses using a Unimar Pipelle just prior to
laparoscopy. The peritoneal cavity and reproductive
organs were visualized by laparoscopy and the absence of
any lesions or adhesions was documented by video
recording. Under laparoscopic guidance, menstrual tissue
was deposited from the Pipelle at four sites; the pouch of
Douglas, the uterine fundus, the cul de sac, and the ova-
ries. At the subsequent mense, the animals underwent a
second laparoscopy and endometrial reseeding at the
same ectopic sites. The progression of disease was moni-
tored in animals by several consecutive laparoscopies over
a period of 15 months after inoculation, during the win-
dow of uterine receptivity (days 9–11 post-ovulation
(PO) in the baboon). Following each laparoscopy a
laparotomy was performed when ectopic endometriotic
lesions and matched eutopic endometrium was harvested
by endometriectomy.
Intraperitoneal inoculation resulted in the formation of
endometriotic lesions with gross morphological charac-
teristics similar to those seen in women (Figure 1). The
development of these endometriotic lesions was observed
in all 24 animals that have undergone intraperitoneal
inoculation. The number and type of lesions ranged
between animals, but on average we observed two red,
three blue, one chocolate, one white and two lesions of
mixed pigmentation during each laparoscopy. Signifi-
cantly more red lesions, which are thought to representReproductive Biology and Endocrinology 2006, 4(Suppl 1):S7
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the most active site of disease, were observed three
months following inoculation with menstrual
endometrium (Figure 2b), while at six months of disease
significantly more blue endometriotic lesions were
present (Figure 2c). Thereafter similar levels of red, blue,
chocolate, white, and mixed lesions were observed,
although there was a trend towards an increased number
of red lesions, indicating that the disease is still active (Fig-
ure 2d). Morphologically, 67% of the ectopic lesions har-
vested at the time of laparotomy contained both
endometrial glands and stroma (Figure 3).
The effect of endometriotic lesions on markers of uterine
receptivity was evaluated both in cycling baboons
between days 9–11 post-ovulation (PO) and those treated
with chorionic gonadotrophin (CG) to simulate preg-
nancy [23,24]. All laparoscopies and laparotomies were
performed during the window of uterine receptivity (days
9–11 PO) in the baboon). Control endometria were sim-
ilarly harvested from animals with no disease at days 9–
11 PO or during the late proliferative phase of the cycle.
In the following we first discuss developmental aspects of
the endometriotic lesions, including their angiogenic
potential, and then explore the impact this disease may
have on receptivity and fertility.
Development of endometriotic lesions is an 
invasive event
The first steps in the pathogenesis of endometriosis
require attachment and invasion of the peritoneal lining
by endometrial fragments. The mechanism by which inva-
sion of the peritoneum occurs is not fully understood.
Some investigators propose that the peritoneal mesothe-
lium acts as a barrier to refluxed endometrium suggesting
that endometrial attachment only occurs at sites of perito-
neal damage [25]. However, other investigators have
shown rapid attachment and invasion through peritoneal
surfaces by endometrial stromal and epithelial cells. Sub-
sequently, mesothelial cells are thought to integrate into
the endometriotic tissues within the peritoneal layer by a
process referred to as re-epitheliazation [26-29]. These
processes mediating the initial establishment of disease
are clearly invasive events that require breakdown of the
peritoneal basement membrane and underlying extracel-
lular matrix (ECM). Matrix metalloproteinases (MMPs)
are essential for remodeling of the ECM in development,
growth and repair of normal tissues and in inflammatory
and degenerative diseases. Endometrial expression of the
MMPs, and their tissue inhibitors (TIMPs), is normally
tightly regulated throughout the menstrual cycle.
The precise role of the MMPs in the pathophysiology of
endometriosis is not fully understood. However, we and
others have reported aberrant patterns of MMP and TIMP
protein and mRNA expression in eutopic and ectopic
endometriotic tissues. Specifically, we have demonstrated
high levels of MMP-7 in peritoneal endometriotic lesions
in baboons with experimental endometriosis [30]. Fur-
thermore, increased levels of both MMP-3 and MMP-7
were found in the eutopic endometrium of baboons with
disease during the window of uterine receptivity when
compared to cycle matched endometrium from control,
disease-free animals [30]. These data were independently
validated by Bruner-Tran et al., [31] who demonstrated
increased MMP-3 and -7 protein and mRNA levels in the
secretory eutopic endometrium of women with endome-
triosis. Other investigators have also shown increased lev-
els of various MMPs and decreased levels of TIMPs in
endometrium from patients with endometriosis com-
pared to tissues from patients with no evidence of disease
[32-37].
Blockade of MMP activity with TIMP-1 reduced the devel-
opment of lesions in the experimental model of endome-
triosis in the ovariectomised nude mouse; furthermore,
specific inhibition of "classical" MMPs (MMP-1, -2, -3, -7,
and -13) with MMP inhibitor III reduced the development
of endometriosis-like lesions in an in vitro invasion assay,
the chicken chorioallantoic membrane (CAM) assay
[37,38]. It has recently been proposed that endometrial
MMP expression is regulated by tumor necrosis factor-α
(TNFα) [33,39]. Studies in the rat and baboon have tar-
geted TNFα activity for the prevention and treatment of
endometriosis. Indeed, recombinant human TNF binding
protein 1 (rhTBP1), the soluble form of TNFα receptor-
type 1, reduced the size of endometriotic-like peritoneal
lesions in the rat model of experimental endometriosis
[40]. Furthermore, studies in the non-human primate
demonstrated that antagonism of TNFα with either
rhTBP1 or a fusion protein of TNF receptor-2 conjugated
to human Fc antibody fragments (known as Etanercept)
can reduce the development of experimental endometrio-
sis or progression of spontaneous disease in baboons
[41,42].
Therefore, we propose that the increased levels of MMPs
present in the eutopic endometrium of women and
baboons with endometriosis promote the invasiveness of
endometrial fragments upon retrograde menstruation
into the peritoneal cavity. Inhibition of development of
lesions in both the in vivo rodent and baboon models of
endometriosis and in vitro invasion assays by inhibition of
MMPs further promotes the role of the MMPs in this dis-
ease. However, it is unclear whether the increased levels of
these proteins are a cause or effect phenomenon of
endometriosis.
Angiogenic Profile of Endometriotic Tissues
Angiogenesis is the formation of new blood vessels from
existing vessels and the process is tightly regulated in theReproductive Biology and Endocrinology 2006, 4(Suppl 1):S7
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adult. However, the primate endometrium undergoes
profound vascular remodeling during each menstrual
cycle and it has been proposed that angiogenesis is impor-
tant in the pathophysiology of endometriosis. Indeed,
endometriotic lesions appear to be surrounded by perito-
neal blood vessels (Figure 1) and increased levels of
numerous angiogenic factors are well documented in the
peritoneal fluid of women with endometriosis [43-50].
The most potent angiogenic factor identified to date is vas-
cular endothelial cell growth factor-A (VEGF). VEGF is
thought to play a critical role in the vascular remodeling
that occurs during each menstrual cycle in normal
endometrium. Several investigators have demonstrated
increased levels of VEGF in ectopic endometriotic lesions
[51-55]. We have confirmed these findings in the baboon
model of endometriosis. Whilst we demonstrated
increased levels of VEGF in all ectopic lesions compared to
control and eutopic matched endometriotic
endometrium throughout progression of disease, maxi-
mal levels were observed in the more active red lesions
[56].
More recently, the angiogenic factor CYR61, a member of
the CCN family of growth factors involved in develop-
ment, proliferation and tumorigenesis, has been shown to
be up-regulated in eutopic and ectopic endometria of
women with endometriosis [57]. Expression of CYR61
mRNA is rapidly induced in an immediate early response
manner by a spectrum of stimuli including growth factors,
cytokines and estrogens [58-60]. We have demonstrated
cyclical regulation of CYR61 in baboon endometrium,
with maximal mRNA levels observed in shed menstrual
Laparoscopic Evaluation of Lesions in a Baboon Model of Experimental Endometriosis Figure 1
Laparoscopic Evaluation of Lesions in a Baboon Model of Experimental Endometriosis. Visualization of the perito-
neal cavity by laparoscope demonstrated the presence of powder burns (identified by a single asterisk) and blue (identified by 
the arrow) and chocolate lesions (identified by the double asterisks) within three (A,B) and six (C,D) months of induction of 
disease.
A
*
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endometrium [56]. CYR61 protein, which is primarily
localized in the epithelial and vascular compartments of
the baboon endometrium, showed cyclical regulation in
both its level and distribution. Specifically, CYR61 protein
is diffusely distributed in glands from the proliferative
phase but is located at the apical edge of endometrial
glands from the secretory phase. Furthermore, CYR61 was
immunolocalized to the endothelial cells of small arteri-
oles throughout the cycle, while larger vessels and spiral
arteries were only immunopositive for CYR61 in men-
strual endometrium. CYR61 mRNA and protein levels
were increased in a time dependent manner in the eutopic
endometrium, during the window of receptivity, of
baboons experimentally induced with endometriosis
[56]. In eutopic endometria of diseased animals, maximal
up-regulation of CYR61 was observed at three months fol-
lowing inoculation, with a mean 6.3-fold increase in
mRNA levels compared to cycle matched control endome-
tria. CYR61 mRNA and protein levels then decreased in
eutopic endometria throughout progression of disease,
with a mean 3-fold up-regulation 15 months after induc-
tion of disease. In the ectopic endometriotic lesions, mean
expression levels of CYR61  mRNA were 3-fold greater
than in eutopic endometrium of endometriotic animals
and 11.7-fold greater than in eutopic endometrium from
normal control animals [56]. The highest levels of CYR61
mRNA was observed in the highly vascularized red
lesions, with a mean expression level of 18.46 (0.96 –
41.26 n = 8). White ectopic lesions, which are thought to
represent the less active sites of disease, demonstrated the
lowest levels of CYR61, with a mean expression of 0.74
(0.46, 1.01, n = 2). Immunohistochemical analysis of the
ectopic lesions showed a similar distribution of CYR61
protein to that in eutopic endometrium, with immunos-
taining primarily in the glandular epithelial and vascular
endothelial cells. The increased levels of CYR61 correlate
with increased levels of VEGF in both the ectopic and
eutopic endometrium of baboons with experimental
endometriosis.
Increased levels of angiogenic factors such as CYR61 and
VEGF in ectopic endometriotic lesions presumably pro-
mote an increase in the peritoneal vascular network,
thereby facilitating implantation and viability of the
refluxed endometrium. Indeed, the use of anti-angiogenic
compounds, including soluble flt-1 (VEGF-receptor 1),
anti-VEGF antibody, TNP-40, endostatin, and angiostatin
have demonstrated the importance of angiogenic proc-
esses in the establishment of endometriosis in the mouse
[61-67]. The impact of increased angiogenic activity
within the eutopic endometrium is unclear. Increased lev-
els of angiogenesis are well documented in the eutopic
endometrium of women with endometriosis [51,52,68-
70]. In addition to CYR61 and VEGF, we have demon-
strated increased levels of the chemokine, eotaxin, which
has been shown to stimulate angiogenic activity in
human, mouse, rat, and chick endothelial cells, in the
eutopic endometrium of baboons experimentally induced
with endometriosis [71,72]. Jones et  al., [73] demon-
strated increased levels of eotaxin in women treated in vivo
with the progestin-only contraceptive pill, which is associ-
ated with breakthrough bleeding. Increased levels of
CYR61, VEGF, and eotaxin in eutopic endometriotic
endometrium may increase the angiogenic potential of
the tissue and further potentiate the development of
lesions. Furthermore, an aberrant angiogenic profile may
be detrimental to an implanting embryo, such that altered
angiogenesis may, in part, mediate the infertility that is
associated with endometriosis.
Coordinated Gene Dysregulation in Eutopic 
Endometrium Leads to Reduced Fertility in 
Endometriosis
Multiple factors have been implicated in endometriosis-
associated infertility, including distortion of the pelvic
anatomy, abnormalities of hormone secretion and action,
alterations in peritoneal fluid, and disorders of fertiliza-
tion and immunoregulatory function [74-77]. Examina-
tion of eutopic endometrium from women with
endometriosis has revealed defects, including dysyn-
chrony of angiogenic phenotype as described above,
ultrastructural abnormalities [78], and alterations in
molecular markers of endometrial receptivity. The latter
include αvβ3 integrin distribution patterns, steroid hor-
mone receptors (SHRs), and HOXA10 gene expression, all
of which are aberrant in the endometrium of women with
endometriosis [68,79-88].
Dysregulation of Steroid Hormone Receptors in 
Endometriosis
We have shown altered SHR protein distribution during
the window of receptivity in baboons with endometriosis.
Specifically, we have observed a time dependent reduc-
tion in estrogen receptor-α (ESR1) immunostaining
within endometrial stromal cells from one month post
induction of disease; this decrease reached statistical sig-
nificance within six months of disease and remained
throughout the time course of disease to 15 months.
Estrogen receptor-β (ESR2) staining was reduced in both
epithelial and stromal cells. Whilst we observed compara-
ble levels of progesterone receptor-B (Pgr-B) in endome-
triotic and control eutopic endometria, diminished Pgr-A
immunostaining of glandular epithelial cells was demon-
strated in endometriotic tissues when compared to con-
trol tissues [89]. Unlike alterations in VEGF and CYR61,
this aberrant SHR profile was not observed until six
months following induction of disease. We propose that
the diminished levels of ESR1, ESR2, and Pgr-A act in con-
cert to create a uterine environment that is non-receptive
to an implanting embryo. Estrogenic and progestogenicReproductive Biology and Endocrinology 2006, 4(Suppl 1):S7
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events are coordinated by complex paracrine interactions
between endometrial stromal and epithelial cells [90]. We
propose that reduced levels of ESR1 within endometrial
stromal cells mediates the reduction of the estrogen-regu-
lated gene Pgr-A in the endometrial epithelial cells. Many
estrogen-regulated genes are thought to be suppressed in
the secretory endometrium under the influence of proges-
terone. We propose that in the absence of Pgr-A within the
epithelial compartment, estrogen-regulated genes, such as
MMPs, VEGF, and CYR61, are no longer subjected to pro-
gesterone-mediated suppression, creating a uterine envi-
ronment that is not conducive to the establishment of
pregnancy.
Aberrant Endometrial Immunological Responses in 
Endometriosis
Infertility has been associated with aberrant expression of
immune modulators, including leukemia inhibitory fac-
tor (LIF), soluble gp130, and IL-11 [91-93]. Many studies
have shown aberrant levels of cytokines in the peritoneal
cavity of women with endometriosis compared to those of
control women, including IL-1, IL-6, IL-10, p40, tumor
necrosis factor-α (TNFα), and transforming growth factor-
β (TNFβ) [49,94-97]. The chemotactic activity of perito-
neal fluid of patients with endometriosis is higher than
that of women with no disease [98]. Correspondingly, it
is well documented that there is a greater number of mac-
rophages in the peritoneal cavity of women with endome-
triosis than in that of women with no disease [99-101].
We proposed that the inflammatory peritoneal environ-
ment created by the presence of endometriotic lesions
induces a uterine immunological environment that is not
conducive to the establishment of pregnancy. Indeed,
microarray analysis of human endometrium obtained
during the window of receptivity has shown a 50-fold
decrease in the mRNA levels of the immunosuppressive
Characterization of Lesions Visualized by Laparoscope in Baboons Experimentally Induced with Endometriosis Figure 2
Characterization of Lesions Visualized by Laparoscope in Baboons Experimentally Induced with Endometrio-
sis. Laparoscopic evaluation of the peritoneal cavity of baboons a) one month following induction of disease revealed similar 
levels of red, blue, chocolate, white, and mixed lesions. The peritoneal cavity contained a significantly higher number of red 
lesions b) three months following induction of endometriosis; however, c) 6 months after inoculation with menstrual 
endometrium significantly higher numbers of blue lesions were present in the peritoneal cavity of baboons with induced dis-
ease. Similar numbers of each lesions type were visible by laparoscopy d) 15 months after induction of endometriosis. Columns 
represent the mean number of red, blue, chocolate, white, and mixed lesions visualized by laparoscope a) 1 month (n = 6), b) 3 
months (n = 21), c) 6 months (n = 10), and d) 15 months (n = 5) after induction of disease. Error bars represent the standard 
error of the mean. (*, p < 0.05, Kruskal-Wallis ANOVA, with Dunn's Correction for multiple testing.)
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molecule Glycodelin A (GdA) in women with endometri-
osis compared to those without [102]. Furthermore, in
eutopic endometrium CG failed to induce GdA in an in
vivo  simulated model of pregnancy in baboons with
endometriosis [103]. GdA has multiple immunosuppres-
sive effects and its abundant presence at the fetal-maternal
interface suggests a role in protecting the embryo from
maternal immune rejection [104-110].
To determine if the development of endometriosis is asso-
ciated with an inflammatory uterine environment we
examined the expression of a panel of immunological fac-
tors involved in the T helper (Th) 1, Th2, and Th3 path-
ways in the eutopic endometrium of baboons with and
without endometriosis. Six months following induction
of disease 11 of the 90 genes represented on the array were
differentially expressed during the window of receptivity
between control and endometriotic eutopic endometria:
one gene was down-regulated and 10 were up-regulated.
IL-1R1 mRNA levels were down-regulated 5-fold in
eutopic endometriotic endometrium, while those of
NFkB, eotaxin, and members of the activating protein-1
(AP-1) family, junD, c-fos and JNK2, were up-regulated
3.0-, 7.9-, 2.3-, and 1.8-fold, respectively [71]. Surpris-
ingly, we saw no difference in the expression of factors
thought to be important in inflammatory processes; this is
most likely a result of the absence of a pre-decidual
response in the baboon. Unlike the human, where a pre-
decidual response in the secretory phase of the menstrual
cycle is accompanied by an increased inflammatory cell
Histological Evaluation of Endometriotic Lesions Figure 3
Histological Evaluation of Endometriotic Lesions. Panel A is a section through a chocolate lesion harvested 
from the uterine surface at three months. Panels B and C are sections through blue lesions obtained at six months of 
disease from the uterine fundus (B) and 12 months of disease in peritoneal fat (C). Panel D is a section through a red lesion 
obtained at 16 months of disease from the peritoneal wall. The presence of endometriotic tissue is histologically confirmed by 
the presence of endometrial glands (indicated with arrows) and stroma (highlighted with asterisks): the stroma surrounding 
glands of endometriotic lesions ranges from only a few cells (as in B) to several cells in depth (as in C).
*
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infiltrate and stromal cell differentiation, the baboon
requires the presence of the embryonic signal to undergo
such changes.
As described above, IL-1R1 was down-regulated in the
eutopic endometrium of baboons experimentally induced
with endometriosis [71]. Studies in mice indicate that
intraperitoneal injection of IL-1 receptor antagonist (IL-
1Ra) prevents implantation by perturbations in the epi-
thelial cell integrin expression [111]. Furthermore,
cytokine-induced apoptosis of epithelial cells is blocked
by the IL-1Ra [112]. Reduction of IL-1R1 in the eutopic
endometrium of baboons with induced endometriosis
may increase the proliferative index of the endometrium;
furthermore, aberration of αvβ3 expression seen in
women with endometriosis may be mediated by the
reduction of IL-1β signaling in the absence of IL-1R1. We
have previously shown the importance of IL-1β in the
simulated model of pregnancy in the baboon, where
antagonism of IL-1β with the IL-1Ra suppresses the effects
of CG on the morphological transformation of the
endometrium, such as the formation of the epithelial
plaque and stromal cell differentiation into a decidual
phenotype [113]. Therefore, we propose that the reduced
levels of endometrial IL-1R1 observed in baboons with
endometriosis provide further evidence that this
endometrium is incapable of responding to and/or medi-
ating signals generated from the implanting embryo.
NFκB mRNA levels were 3-fold greater in the eutopic
endometrium of baboons with experimental endometrio-
sis than in that of baboons with no disease [71]. NFκB is
a ubiquitously expressed transcription factor that can be
activated in a wide variety of cell types and has been
shown to regulate the expression of a wide variety of genes
in mammalian immune and inflammatory responses,
including cytokines, cell adhesion molecules, comple-
ment factors, immuno-receptors and anti-apoptotic fac-
tors [114]. Progesterone controls endometrial
development, in part, by inhibition of the NFκB pathway
[115-117]. We propose that the decreased levels of Pgr-A
in the eutopic endometrium of baboons with endometri-
osis mediates the increased levels of NFκB. Increased
NFκB may reduce the apoptotic potential of endometri-
otic tissues. Indeed, eutopic endometrium from women
with endometriosis appears to be resistant to apoptosis
and shows aberrant expression of genes involved in the
apoptotic pathway [118-122]. Furthermore, inhibition of
NFκB decreased endometriotic lesion development in the
nude mouse model of endometriosis [123]. Inactivation
of the NFκB response element in the promoter of the
inflammatory cytokine RANTES, which is up-regulated in
endometriotic stromal cells, by mutagenesis or progestin
treatment leads to suppression of RANTES production in
endometriotic and normal endometrial stromal cells
[124,125]. Therefore, we propose that increased levels of
endometrial NFκB in baboons with endometriosis is
mediated by reduced Pgr-A levels and leads to an inflam-
matory and proliferative type endometrium.
The AP-1 Family of Transcription Factors in Endometriosis
Micro-array analysis demonstrated a 2.3-fold increase in c-
fos mRNA in the eutopic endometrium six months follow-
ing induction of endometriosis [71]. C-fos is an estrogen-
induced early response gene that mediates estrogen-regu-
lated proliferation in normal and malignant breast and
endometrial cells [126-132]. An increased level of c-fos in
endometriotic endometrium during the window of recep-
tivity provides further evidence to support the hypothesis
that the endometrial environment of baboons and
women with endometriosis is hyper-estrogenic. There-
fore, we examined the expression and distribution of c-fos
throughout progression of experimental endometriosis in
the baboon. C-fos protein was immunolocalized to both
the epithelial and stromal cells in normal secretory
baboon endometrium. Corresponding to the microarray
analysis, increased levels of c-fos protein were present in
the eutopic endometrium of animals six months follow-
ing induction of disease compared to control tissues.
Although c-fos protein was present in endometrium from
baboons 15 months after inoculation, the level of immu-
nostaining was similar to that seen in control, disease-free
endometrium [71]. Likewise, c-fos  mRNA was differen-
tially expressed in the eutopic endometrium throughout
progression of endometriosis. Maximal c-fos  mRNA
expression was observed at three months of disease, with
a statistically significant 483-fold up-regulation over con-
trol samples. C-fos  mRNA then gradually decreased
throughout progression of disease to a 93- and 60-fold
increase at six and 12 months, respectively. Fifteen
months after induction of endometriosis levels of c-fos
mRNA expression were almost the same as those found in
control tissues from animals with no disease [71].
C-fos, together with junD and JNK2, are members of the
AP-1 family of proteins which play a critical role in con-
trolling cell life and death. In addition to being a tran-
scriptional activator, AP-1 appears to induce gene
repression or silencing. Furthermore, c-fos has been
shown to inhibit Pgr-induced transcription [133]. As
described above, Pgr-A was decreased in the eutopic
endometrial epithelial cells within six months of disease
[89]. We propose that in the very early stages of disease,
when the levels of Pgr-A are similar in endometriotic and
control endometrium, that increased levels of c-fos may
inhibit the ability of Pgr-A to mediate the transcription of
progesterone-regulated genes. This inactivity would pro-
vide another mechanism whereby Pgr-A activity is inhib-
ited; ESR-1-induced genes, such as MMPs, VEGF, and
CYR61, would then be expressed in the endometrium dur-Reproductive Biology and Endocrinology 2006, 4(Suppl 1):S7
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ing the window of receptivity, even when there appears to
be no differences in the expression level of the SHRs.
C-fos transformation of rat fibroblasts induces the expres-
sion of DNA 5-methylcytosine transferase (dnmt1), which
causes hypermethylation and subsequent repression of
gene expression by promoting the condensation of chro-
matin [134-136]. Wu et al [137] recently demonstrated
that the reduction of HOXA10 mRNA and protein seen in
women with endometriosis was associated with hyper-
methylation of the HOXA10 gene. We have examined the
expression of HOXA10 in eutopic endometrium of
baboons with experimental endometriosis. We observed a
progressive, statistically significant loss of HOXA10
mRNA and protein throughout the progression of
endometriosis from three to 15 months [138]. This con-
firmed preliminary microarray analysis using the Affyme-
trix gene chip HUM199A, which identified a 2.4-fold
down-regulation in HOXA10 mRNA one month after
induction of disease [138]. We propose that up-regulation
and activity of c-fos seen in the baboon model of endome-
triosis may induce the expression of dnmt1 and subse-
quent hypermethylation and down-regulation of
endometrial HOXA10 and other progesterone-regulated
genes.
Conclusion
We propose that the development of endometriotic
lesions within the peritoneal cavity is a highly invasive
process. Using the baboon model of experimental
endometriosis we have demonstrated that the invasive
phenotype is mediated by MMPs. The development of a
supporting vasculature is mediated, in part by VEGF and
CYR61. The impact of these peritoneal lesions on the
eutopic endometrium is clearly illustrated by the reduced
level of fertility observed in women and baboons with
endometriosis. However, the mechanisms by which the
presence of disease alters the eutopic endometrium is
unclear. We have demonstrated aberrant expression pro-
files of many estrogen and progesterone regulated genes
during the window of receptivity in baboons with experi-
mental endometriosis. VEGF, CYR61 and c-fos show tran-
sient increases during the early stages of disease, while
changes in other genes, including ESR1, Pgr-A, and
HOXA10, develop at later stages of disease (Figure 4). Fur-
thermore, we have shown irregular responses within the
endometrium to embryonic signals. In conclusion, these
data suggest that, in an induced model of endometriosis
in the baboon, an increased angiogenic capacity,
decreased apoptotic potential, progesterone resistance,
estrogen hyper-responsiveness, and an inability to
respond appropriately to embryonic signals mediates the
reduced fecundity associated with this disease.
However, several questions remain to fully understand
the impact of endometriotic lesions on the eutopic
endometrium. Firstly, are these aberrant gene expression
patterns a cause or effect of endometriosis; i.e. does the
eutopic endometrium have an inherent abnormal pheno-
type or is it induced upon translocation to the peritoneal
cavity? It is not possible to address this question in
women as most present to the clinic with well established
disease. We propose that it is the establishment of disease
itself that actuates the anomalous activity of the eutopic
endometrium. Although the studies in the baboon model
of endometriosis described above allow the investigation
of the very early stages of disease, current ongoing studies
in our laboratory are analyzing the endometrium har-
vested from the same animal before and after induction of
endometriosis to more completely address this question.
Secondly, the mechanisms whereby the ectopic
endometrium communicates with the eutopic
endometrium are unclear. It has been suggested that com-
munication and transfer between the peritoneal and uter-
ine cavities occurs in both directions, such that factors
secreted in the peritoneal fluid, which baths the reproduc-
tion organs, enters the fallopian tubes and reaches the
endometrium. It is also possible that ectopic lesions,
which we and others have shown are highly vascularized,
may communicate with the eutopic endometrium in an
endocrine manner, via their newly formed vascular net-
works. Thirdly, we have described altered expression pat-
terns of several estrogen and progesterone regulated genes
in the early stages of disease progression, when the steroid
hormone receptors themselves appear to be normal.
Rapid non-genomic effects of estrogen and progesterone
have been identified in many mammalian tissues [139-
141]. It is possible that transcription of these hormonally
regulated genes occurs at a non-genomic level; alterna-
tively, these genes could be regulated by a non-hormonal
mechanism.
We believe that the baboon model of experimental
endometriosis provides a powerful model to understand
the early events associated with the pathophysiology of
endometriosis and its associated infertility.
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